Concurrent chemoradiation followed by durvalumab yields objective responses in only ~30% of stage III unresectable NSCLC, while toxicity and normal-tissue constraints preclude meaningful radiation ...

Cancer care complexity arises from multiple disease subtypes, expanding therapeutic sequences, and individualized constraints from comorbidities, concurrent medications, and drug–drug interactions.

Independent radiology review showed 94% ORR (15% CR) in 94 TKI-naïve ROS1+ NSCLC patients receiving 100 mg daily, with median DoR and PFS not reached. Central nervous system efficacy was robust: 10/10 ...

I have been living with stage IV kidney cancer for more than ten years. By now, I have had more CT scans, MRIs, PET scans, blood tests and follow-up appointments than I could ever count. You would ...

After facing multiple cancers and hospice care, April Floyd credits her service dog Onyx with helping her find comfort, strength and hope. Years before Onyx entered my life, I lost my beloved dog ...

Three new studies from WCLC 2026 show strong results in ROS1-positive NSCLC, EGFR-mutant NSCLC and relapsed small cell lung ...

FDA approves Inluriyo plus Verzenio for adults with ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast ...

In this Q&A, Dr. Dina Khalaf, a clinical associate professor in the University of Florida Division of Hematology and Oncology ...

Expanded timing includes annual MRD testing during maintenance and after subsequent therapy lines, including following CAR-T, to enable serial assessment rather than single timepoint interpretation.

After having cancer, travelling can become more than a getaway. It can be part of your emotional recovery. Rest, joy, and ...

Local transplant availability reduced patient travel burden and preserved continuity for long-term oncology relationships, reinforcing the program’s mission around access and community-based care.

Progression-free survival reached 14.3 months with Enhertu versus 8.3 months with chemotherapy plus Keytruda in HER2-mutant lung cancer. Dr. Julia Rotow, a thoracic medical oncologist at Dana-Farber ...